These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23301057)

  • 1. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.
    Loi S; Michiels S; Baselga J; Bartlett JM; Singhal SK; Sabine VS; Sims AH; Sahmoud T; Dixon JM; Piccart MJ; Sotiriou C
    PLoS One; 2013; 8(1):e53292. PubMed ID: 23301057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
    López-Knowles E; Segal CV; Gao Q; Garcia-Murillas I; Turner NC; Smith I; Martin LA; Dowsett M
    Breast Cancer Res; 2014 Jun; 16(3):R68. PubMed ID: 24981670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: an experimental study.
    Liu Y; Zhang X; Liu J; Hou G; Zhang S; Zhang J
    Tumour Biol; 2014 Feb; 35(2):1275-86. PubMed ID: 24014089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
    Wheler JJ; Moulder SL; Naing A; Janku F; Piha-Paul SA; Falchook GS; Zinner R; Tsimberidou AM; Fu S; Hong DS; Atkins JT; Yelensky R; Stephens PJ; Kurzrock R
    Oncotarget; 2014 May; 5(10):3029-38. PubMed ID: 24912489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
    J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Loi S; Haibe-Kains B; Majjaj S; Lallemand F; Durbecq V; Larsimont D; Gonzalez-Angulo AM; Pusztai L; Symmans WF; Bardelli A; Ellis P; Tutt AN; Gillett CE; Hennessy BT; Mills GB; Phillips WA; Piccart MJ; Speed TP; McArthur GA; Sotiriou C
    Proc Natl Acad Sci U S A; 2010 Jun; 107(22):10208-13. PubMed ID: 20479250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
    Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
    Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.
    Treilleux I; Arnedos M; Cropet C; Wang Q; Ferrero JM; Abadie-Lacourtoisie S; Levy C; Legouffe E; Lortholary A; Pujade-Lauraine E; Bourcier AV; Eymard JC; Spaeth D; Bachelot T
    Ann Oncol; 2015 Jan; 26(1):120-125. PubMed ID: 25361980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
    Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
    Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Guarneri V; Generali DG; Frassoldati A; Artioli F; Boni C; Cavanna L; Tagliafico E; Maiorana A; Bottini A; Cagossi K; Bisagni G; Piacentini F; Ficarra G; Bettelli S; Roncaglia E; Nuzzo S; Swaby R; Ellis C; Holford C; Conte P
    J Clin Oncol; 2014 Apr; 32(10):1050-7. PubMed ID: 24590635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple gene aberrations and breast cancer: lessons from super-responders.
    Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
    BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
    Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones.
    Cavazzoni A; Bonelli MA; Fumarola C; La Monica S; Airoud K; Bertoni R; Alfieri RR; Galetti M; Tramonti S; Galvani E; Harris AL; Martin LA; Andreis D; Bottini A; Generali D; Petronini PG
    Cancer Lett; 2012 Oct; 323(1):77-87. PubMed ID: 22484466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
    Generali D; Berruti A; Cappelletti MR; Zanotti L; Brugnoli G; Forti M; Bedussi F; Vailati ME; Milani M; Strina C; Ardine M; Aguggini S; Allevi G; Ferrero G; Bertoni R; Bottini A; Harris AL; Fox SB
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):64-6. PubMed ID: 26063890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic in vitro anti-tumor effect of letrozole and everolimus on human endometrial carcinoma Ishikawa cells.
    Lu XY; Yang Y; Xu H; Zeng T; Zhang ZZ
    Eur Rev Med Pharmacol Sci; 2014 Aug; 18(16):2264-9. PubMed ID: 25219824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III
    Ma CX; Suman V; Goetz MP; Northfelt D; Burkard ME; Ademuyiwa F; Naughton M; Margenthaler J; Aft R; Gray R; Tevaarwerk A; Wilke L; Haddad T; Moynihan T; Loprinzi C; Hieken T; Barnell EK; Skidmore ZL; Feng YY; Krysiak K; Hoog J; Guo Z; Nehring L; Wisinski KB; Mardis E; Hagemann IS; Vij K; Sanati S; Al-Kateb H; Griffith OL; Griffith M; Doyle L; Erlichman C; Ellis MJ
    Clin Cancer Res; 2017 Nov; 23(22):6823-6832. PubMed ID: 28874413
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.